6 Apr 2009 | A New Point-of-Care Sensing Technology from the London Centre for Nanotechnology
Researchers from the London Centre for Nanotechnology, a joint venture between UCL (University College London) and Imperial College London, and their research partners have been awarded the Nanotechnology for Healthcare grant from the EPSRC's Grand Challenge Competition. The research will bring biomedical engineers, physicists, chemists, virologists and clinicians together to create a device that uses nano-cantilever arrays, to measure HIV and other protein markers that can indicate a rise in the level of the virus and the body's response to it.
daVinci Ventures was engaged in October 2008, by UCL Business, to carry out a market research exercise into a point-of-care product based on the nano-cantilever array technology. In addition to its application in detecting HIV other infectious diseases the research identified huge potential in multi-marker testing for cancer. The EPSRC award underpins the potential for this innovative technology and will allow the sensor platform to be developed in the lead up to further commercialisation work.
For more information click here
« back
Researchers from the London Centre for Nanotechnology, a joint venture between UCL (University College London) and Imperial College London, and their research partners have been awarded the Nanotechnology for Healthcare grant from the EPSRC's Grand Challenge Competition. The research will bring biomedical engineers, physicists, chemists, virologists and clinicians together to create a device that uses nano-cantilever arrays, to measure HIV and other protein markers that can indicate a rise in the level of the virus and the body's response to it.
daVinci Ventures was engaged in October 2008, by UCL Business, to carry out a market research exercise into a point-of-care product based on the nano-cantilever array technology. In addition to its application in detecting HIV other infectious diseases the research identified huge potential in multi-marker testing for cancer. The EPSRC award underpins the potential for this innovative technology and will allow the sensor platform to be developed in the lead up to further commercialisation work.
For more information click here
« back
